BRIEF-EMA Starts Review Of Vir-7831 For Treating Patients With COVID-19

European Medicines Agency: * EMA SAYS STARTS REVIEW OF VIR-7831 FOR TREATING PATIENTS WITH COVID-19

* EMA SAYS REVIEWING CURRENTLY AVAILABLE DATA ON USE OF MONOCLONAL ANTIBODY VIR-7831 (ALSO KNOWN AS GSK4182136) IN TREATMENT OF PATIENTS WITH COVID-19 * EMA- CHMP TO LOOK AT HOW WELL MEDICINE PREVENTS HOSPITALISATION, DEATH IN NON-HOSPITALISED COVID-19 PATIENTS WHO DO NOT REQUIRE OXYGEN SUPPLEMENTATION

* EMA SAYS THE CHMP WILL ALSO CONSIDER DATA ON THE MEDICINE’S QUALITY AND SAFETY * EMA SAYS CURRENT REVIEW WILL PROVIDE EU-WIDE RECOMMENDATIONS FOR NATIONAL AUTHORITIES WHO MAY TAKE EVIDENCE-BASED DECISIONS ON EARLY USE OF VIR-7831 Source text: (https://bit.ly/3e0jtwy) Further company coverage:

Also Read: List blood clots as 'very rare side effect' of AstraZeneca vaccine, advises European Medicines Agency